MetLife, Inc. (MET) AI Stock Analysis

MetLife, Inc., founded in 1863 and headquartered in New York, New York, is a financial services provider delivering insurance, annuities, employee benefits, and asset management solutions globally. The company operates across five operational segments: U.S., Asia, Latin America, Europe, the Middle East and Africa, and MetLife Holdings. Its product portfolio includes life insurance, dental plans, group and individual disability coverage, pet insurance, vision care, and accident and health policies. MetLife also offers prepaid legal plans, pension risk transfers, institutional income annuities, structured settlements, capital markets investment products, regular savings plans, longevity reinsurance, and credit insurance products.

Between FY2021 and FY2025, MetLife expanded annual revenue from $63.37B to $77.08B, producing a 5-year revenue CAGR of 2.6%. Annual net income moved from $6.86B in FY2021 to $1.58B in FY2023, before recovering to $4.43B in FY2024 and $3.38B in FY2025. Gross margin widened from 26.6% in FY2021 to 36.4% in FY2025, while operating margin finished at 6.0% in FY2025 compared to 13.4% in FY2021. For the latest quarter ended June 30, 2026, quarterly revenue grew 10.5% year-over-year, and quarterly earnings grew 5.8% year-over-year. Over the trailing twelve months, revenue reached $79.40B with a profit margin of 4.6% and EPS of $5.22.

As of June 30, 2026, MetLife held $129.53B in cash and short-term investments against total debt of $21.34B, leaving net cash of $108.18B. Shareholders' equity was $27.44B out of $759.37B in total assets, with a debt-to-equity ratio of 0.78 and a current ratio of 0.65. Operating cash flow and free cash flow both totaled $18.11B in FY2025. MetLife deployed cash in FY2025 toward $3.88B in share buybacks and $1.70B in dividends paid, contributing to a 5-year share count change of -22.4%.

MetLife shares closed at $100.76 on October 16, 2026, representing a market cap of $64.03B and an enterprise value of $81.88B. Its trailing P/E of 19.3x sits above the 14.2x median of its S&P 500 Financial Services peers, but its forward P/E of 10.5x is lower than the peer median of 12.6x. The stock trades at a price-to-sales multiple of 0.8x compared to the peer median of 3.1x. Over the past 1-year period, MetLife gained 33.1%, outperforming the S&P 500 return of 16.8%, while its 5-year return of 78.6% trailed the index return of 83.0%.

MetLife provides an annual forward dividend of $2.37 per share, yielding 2.35% with a payout ratio of 24.2%. Dividends are distributed on a quarterly schedule, and the company has maintained 27 consecutive years of payments. The annualized 5-year dividend growth rate is 4.3%, with the last ex-dividend date recorded on November 3, 2026.

Wall Street analyst ratings comprise 8 Strong Buy, 5 Buy, 4 Hold, 1 Sell, and 0 Strong Sell recommendations. The consensus mean price target is $107.38, indicating a 6.6% upside from the last close of $100.76. For the fiscal year ending December 31, 2026, analysts estimate EPS of $10.21 on revenue of $79.73B. MetLife has topped EPS estimates in 4 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of MetLife, Inc. (MET). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MET income statement, MET balance sheet, MET key metrics, MET analyst forecast, MET chart. See the MET stock overview for the latest quote and news.